2. Search Result
Search Result
Results for "

Pancreatic ductal adenocarcinoma (PDAC)

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101194
    Tin protoporphyrin IX dichloride
    Maximum Cited Publications
    19 Publications Verification

    Tin-protoporphyrin IX; Sn-Protoporphyrin; SnPPIX

    		 Reactive Oxygen Species Cancer
    Tin protoporphyrin IX dichloride (SnPPIX) is a potent Heme oxygenase-1 (HO-1) inhibitor. Tin protoporphyrin IX dichloride sensitizes pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mice model .
    Tin protoporphyrin IX dichloride
  • HY-147008
    XP-524

    		Epigenetic Reader Domain Cancer
    XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .
    XP-524
  • HY-P99379
    Nidanilimab (Nadunolimab)

    CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)

    		 Interleukin Related Cancer
    Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
    Nidanilimab (Nadunolimab)
  • HY-156027
    SIRT6-IN-3

    		Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK Neurological Disease Inflammation/Immunology Endocrinology Cancer
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .
    SIRT6-IN-3
  • HY-122723
    GOT1 inhibitor-1
    2 Publications Verification

    		 Reactive Oxygen Species Cancer
    GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC50 of 8.2 uM. GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC) .
    GOT1 inhibitor-1
  • HY-148260
    KRAS G12D inhibitor 16

    		Ras Cancer
    KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC50 value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC) .
    KRAS G12D inhibitor 16
  • HY-160045
    AP1153 aptamer sodium

    		Cholecystokinin Receptor Cancer
    AP1153 aptamer sodium is a DNA aptamer that specifically binds to the cholecystokinin receptor CCKBR (Kd: ~15 pM), but does not activate CCKBR-related signaling pathways. AP1153 aptamer sodium is internalized by pancreatic ductal adenocarcinoma (PDAC) cells in a receptor-mediated manner. AP1153 aptamer sodium can bioconjugate to the surface of fluorescent nanoparticles to facilitate nanoparticle delivery to PDAC tumors in vivo .
    AP1153 aptamer sodium
  • HY-N6237
    Aspulvinone O

    		Reactive Oxygen Species Infection
    Aspulvinone O is a natural inhibitor of aspartate transaminase 1 (GOT1). GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 may serve as an important target in PDAC. Aspulvinone O suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism .
    Aspulvinone O
  • HY-18652A
    Avutometinib potassium

    Ro 5126766 potassium; CH5126766 potassium

    		 Raf MEK Cancer
    Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .
    Avutometinib potassium
  • HY-161346
    EBET-1055

    		ADC Cytotoxin Epigenetic Reader Domain Cancer
    EBET-1055 is a bromodomain and extra-terminal (BET) protein degrader (EBET) composed of a BET inhibitor (EBET-590, HY-161387), an E3 ubiquitin ligase ligand and connectors. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures .
    EBET-1055
  • HY-148409
    MMRi62

    		Ferroptosis Apoptosis Autophagy MDM-2/p53 Cancer
    MMRi62, a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12 .
    MMRi62
  • HY-135985
    DCLK1-IN-1
    1 Publications Verification

    		 Fluorescent Dye Cancer
    DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC50: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1 + pancreatic ductal adenocarcinoma (PDAC) .
    DCLK1-IN-1
  • HY-168718
    FAK-IN-22

    		FAK JAK Aurora Kinase PI3K Akt Apoptosis Cancer
    FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC). FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway .
    FAK-IN-22
  • HY-145584
    Nesuparib

    JPI-547/OCN-201

    		 PARP Apoptosis Wnt β-catenin Cardiovascular Disease Neurological Disease Cancer
    Nesuparib (JPI-547) is an orally active PARP 1/2 and Tankyrase 1/2 inhibitor involved in the Wnt/β-catenin pathway. Nesuparib can induce cell cycle arrest and apoptosis and has anti-tumor activity. Nesuparib can be used to study cancer, neurological diseases and cardiovascular diseases .
    Nesuparib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: